Biogened (WAR:BGD) Cyclically Adjusted FCF per Share: zł1.49 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:BGD Biogened SA WAR:BGD
68 GF Score
Price zł19.00
GF Value zł24.10
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biogened Cyclically Adjusted FCF per Share?

Biogened WAR:BGD 68 Cyclically Adjusted FCF per Share is zł1.49 as of Mar. 2026. GuruFocus rates WAR:BGD with a GF Score™ of 68/100 and a GF Value™ of zł24.10 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Biogened's adjusted free cash flow per share for the three months ended in Mar. 2026 was zł-0.108. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is zł1.49 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Biogened's average Cyclically Adjusted FCF Growth Rate was 53.60% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 39.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Biogened was 39.70% per year. The lowest was 23.20% per year. And the median was 31.45% per year.

As of today (2026-08-09), Biogened's current stock price is zł19.00. Biogened's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was zł1.49. Biogened's Cyclically Adjusted Price-to-FCF of today is 12.75.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Biogened was 36.34. The lowest was 11.68. And the median was 22.11.


Biogened  (WAR:BGD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Biogened's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=19.00/1.49
=12.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Biogened was 36.34. The lowest was 11.68. And the median was 22.11.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Biogened Cyclically Adjusted FCF per Share Related Terms


Biogened Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Biogened's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogened Cyclically Adjusted FCF per Share Chart

Biogened Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.62 0.51 1.30 1.16 1.39

Biogened Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.97 0.99 1.39 1.49

WAR:BGD vs ZTS, UTHR, VTRS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biogened's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogened Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogened's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biogened's Cyclically Adjusted Price-to-FCF falls into.


WAR:BGD
68GF Score
Biogened SA WAR:BGD
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogened Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogened's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.108/163.0700*163.0700
=-0.108

Current CPI (Mar. 2026) = 163.0700.

Biogened Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -1.034 99.552 -1.694
201609 0.421 99.064 0.693
201612 0.656 100.366 1.066
201703 0.131 101.018 0.211
201706 0.342 101.180 0.551
201709 -0.110 101.343 -0.177
201712 0.770 102.564 1.224
201803 0.165 102.564 0.262
201806 -0.110 103.378 -0.174
201809 0.646 103.378 1.019
201812 0.805 103.785 1.265
201903 0.026 104.274 0.041
201906 0.193 105.983 0.297
201909 0.718 105.983 1.105
201912 0.548 107.123 0.834
202003 0.136 109.076 0.203
202006 0.698 109.402 1.040
202009 1.011 109.320 1.508
202012 0.956 109.565 1.423
202103 -0.405 112.658 -0.586
202106 0.241 113.960 0.345
202109 0.476 115.588 0.672
202112 0.328 119.088 0.449
202203 0.208 125.031 0.271
202206 -0.979 131.705 -1.212
202209 -1.525 135.531 -1.835
202212 0.933 139.113 1.094
202303 0.259 145.950 0.289
202306 -0.678 147.009 -0.752
202309 2.329 146.113 2.599
202312 1.354 147.741 1.494
202403 -1.706 149.044 -1.867
202406 -0.195 150.997 -0.211
202409 -0.028 153.439 -0.030
202412 1.321 154.660 1.393
202503 0.556 157.021 0.577
202506 -1.498 157.509 -1.551
202509 0.355 158.000 0.366
202512 2.672 158.320 2.752
202603 -0.108 163.070 -0.108

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of zł1.49 mean?
Biogened (WAR:BGD) has a Cyclically Adjusted FCF per Share of zł1.49 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Biogened and its competitors.
Is Biogened's Cyclically Adjusted FCF per Share too high?
Biogened's current Cyclically Adjusted FCF per Share is zł1.49. Overall, Biogened has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogened's Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Biogened's Cyclically Adjusted FCF per Share of zł1.49 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Biogened and its competitors. Biogened's current Cyclically Adjusted FCF per Share is zł1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Modestly Undervalued. The stock's GF Value™ is zł24.10, compared to a current price of zł19.00 — trading 21.2% below its estimated fair value. The current Cyclically Adjusted FCF per Share is zł1.49. Biogened's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Biogened (WAR:BGD), the current Cyclically Adjusted FCF per Share is zł1.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogened (WAR:BGD) Overvalued in 2026?

Based on GuruFocus' analysis, Biogened stock appears to be undervalued. The current stock price of zł19.00 is trading 21.2% below its estimated GF Value™ of zł24.10. GuruFocus considers Biogened to be Modestly Undervalued.

Key valuation signals for WAR:BGD:

  • Cyclically Adjusted FCF per Share: zł1.49
  • GF Value™: zł24.10 vs. price of zł19.00 (21.2% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogened Business Description

Address Ulica Pojezierska 99, Lodz, POL, 91-342
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
68GF Score

Get the complete analysis for WAR:BGD

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.00
Price
zł24.10
GF Value